MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ngar Yee Louie bought 19,665 shares of the firm's stock in a transaction on Thursday, April 25th. The stock was acquired at an average cost of $2.03 per share, with a total value of $39,919.95. Following the completion of the purchase, the director now owns 1,167,189 shares of the company's stock, valued at approximately $2,369,393.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
MAIA Biotechnology Trading Up 9.7 %
NYSEAMERICAN:MAIA traded up $0.26 on Friday, reaching $2.94. The company's stock had a trading volume of 437,552 shares, compared to its average volume of 385,844. MAIA Biotechnology, Inc. has a 1-year low of $0.82 and a 1-year high of $3.07. The stock has a market cap of $60.51 million, a price-to-earnings ratio of -1.96 and a beta of 0.42.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). Sell-side analysts forecast that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current year.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
